HC Wainwright Predicts Kamada’s Q1 Earnings (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA) – HC Wainwright lifted their Q1 2026 earnings estimates for Kamada in a note issued to investors on Thursday, March 12th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of $0.14 for the quarter, up from their prior estimate of $0.10. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada’s Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.17 EPS, Q4 2026 earnings at $0.16 EPS and FY2030 earnings at $0.88 EPS.

Several other brokerages also recently weighed in on KMDA. Benchmark reiterated a “buy” rating on shares of Kamada in a research note on Thursday, March 12th. Stifel Nicolaus set a $11.00 price objective on Kamada in a research note on Wednesday, March 11th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a research report on Thursday, January 22nd. Finally, Wall Street Zen downgraded Kamada from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.00.

Kamada Stock Performance

NASDAQ KMDA opened at $8.89 on Monday. The firm’s fifty day moving average is $8.50 and its two-hundred day moving average is $7.49. Kamada has a one year low of $5.54 and a one year high of $9.35. The firm has a market cap of $511.26 million, a PE ratio of 25.40, a P/E/G ratio of 0.68 and a beta of 0.94.

Kamada (NASDAQ:KMDA) last released its quarterly earnings results on Wednesday, March 11th. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). The business had revenue of $44.68 million during the quarter, compared to analysts’ expectations of $145.07 million. Kamada had a net margin of 11.19% and a return on equity of 7.72%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC purchased a new stake in Kamada during the 1st quarter worth approximately $206,000. NewEdge Advisors LLC boosted its holdings in shares of Kamada by 119.9% during the first quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock valued at $341,000 after acquiring an additional 28,165 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of Kamada in the first quarter valued at approximately $497,000. Jane Street Group LLC bought a new stake in shares of Kamada during the first quarter valued at approximately $582,000. Finally, Acadian Asset Management LLC raised its holdings in shares of Kamada by 3.1% during the second quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock valued at $2,053,000 after buying an additional 7,925 shares during the last quarter. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Announces Dividend

The firm also recently announced an annual dividend, which will be paid on Monday, April 6th. Investors of record on Monday, March 23rd will be given a dividend of $0.25 per share. This represents a yield of 292.0%. The ex-dividend date of this dividend is Monday, March 23rd.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.